FDA regulatory application heralds a new contender in ankylosing spondylitis with AbbVie’s Rinvoq

AbbVie is already conducting a Phase III study, SELECT Axis 2, examining the safety and efficacy of Rinvoq in patients with milder axSpA. Credit: Shutterstock.



  • Rinvoq; ankylosing spondylitis